- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03018938
A Study of Basal Insulin Analog and Insulin Analog Mid Mixture in Chinese Participants With Type 2 Diabetes Mellitus (CLASSIC)
Comparison Between Basal Insulin Analog and Insulin Analog Mid Mixture AS Starter Insulin for Chinese Patients With Type 2 Diabetes Mellitus (CLASSIC Study)
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Fase 4
Kontakter og plasseringer
Studiesteder
-
-
-
Beijing, Kina, 102206
- Peking University International Hospital
-
Beijing, Kina
- Beijing Hai Dian Hospital
-
Shanghai, Kina, 200090
- Shanghai Yangpu District Central Hospital
-
-
Beijing
-
Beijing, Beijing, Kina, 100044
- Peking University Peoples Hospital
-
Beijing, Beijing, Kina, 100016
- Beijing Huaxin Hospital
-
Chaoyang, Beijing, Kina, 100028
- China Meitan General Hospital
-
Fangshan, Beijing, Kina, 102500
- Beijing Yanhua Hospital
-
-
Gansu
-
Lanzhou, Gansu, Kina, 730030
- The 2nd Hospital of Lanzhou University
-
-
Guangdong
-
Shenzhen, Guangdong, Kina, 518020
- Shenzhen City People Hospital
-
Yuexiu, Guangdong, Kina, 510080
- The 1st Hospital with Guangdong Pharmaceutical University
-
-
Henan
-
Luoyang, Henan, Kina, 471003
- The 1st Affiliated Hospital of Henan Science and technology
-
Zhengzhou, Henan, Kina, 450003
- People's Hospital of Henan Province
-
-
Hubei
-
Wuhan, Hubei, Kina, 430022
- Wuhan Union (Xiehe) Hospital
-
-
Jiangsu
-
Changzhou, Jiangsu, Kina, 213003
- Changzhou No.2 People's Hospital
-
Nanjing, Jiangsu, Kina, 210001
- Nanjing TCM hospital
-
Nanjing, Jiangsu, Kina, 210024
- Jiang Su Province Official Hospital
-
Nanjing, Jiangsu, Kina, 210048
- Nanjing Jiangbei Hospital
-
Nanjing, Jiangsu, Kina, 211100
- Nanjing Jiangning Hospital
-
Taizhou, Jiangsu, Kina, 225300
- Taizhou City People Hospital
-
Wuxi, Jiangsu, Kina, 214000
- The Second People's Hospital of Wuxi
-
Xuzhou, Jiangsu, Kina, 221009
- Xuzhou Central Hospital
-
-
Shandong
-
Qingdao, Shandong, Kina, 266071
- Qingdao Municipal Hospital
-
Taian, Shandong, Kina, 271000
- Taian City Central Hospital
-
-
Shanghai
-
Shanghai, Shanghai, Kina, 200135
- Shanghai Pudong New Area Gongli Hospital
-
Shanghai, Shanghai, Kina, 201318
- Shanghai Pudong New District Zhoupu Hospital
-
-
Shunqing
-
Nanchong, Shunqing, Kina, 637000
- Affiliated Hospital of North Sichuan Medical College
-
-
Sichuan
-
Chengdu, Sichuan, Kina, 610041
- The Third Affiliated Hospital of Chengdu University of TCM
-
Luzhou, Sichuan, Kina, 646000
- Southwest Medical University Affiliated Hospital
-
-
Tianjin
-
Nankai, Tianjin, Kina, 300192
- Tianjin First Central Hospital
-
-
Tongzhou
-
Beijing, Tongzhou, Kina, 101149
- Beijing Luhe Hospital Capital Medical University
-
-
Zhejiang
-
Hangzhou, Zhejiang, Kina, 310014
- Zhejiang Provincial People's Hospital
-
Ningbo, Zhejiang, Kina, 315010
- Ningbo First Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- have type 2 diabetes as defined by World Health Organization (WHO) criteria
- are taking oral anti-hyperglycemic medications (OAMs) and are judged as OAM failure by the investigator
- most recent HbA1c value ≥7.5% within 12 weeks of study entry
- in the opinion of the investigator, require to initiate premix analog or basal insulin analog treatment
- willing to start with insulin treatment
Exclusion Criteria:
- have a diagnosis of type 1 diabetes
- have received any type of insulin within 24 months of study entry (except for intermittent use of insulin of less than 1 month each time)
- have serious preexisting medical or other conditions that, in the judgment of the investigator, would preclude participation in this study
- are pregnant or breastfeeding, or intend to become pregnant during the course of the study
- are currently enrolled or have participated, within the last 30 days in any other clinical trial involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Insulin Analog Mid Mixture
Insulin analog mid mixture given subcutaneously (SC).
|
Administered SC
|
Eksperimentell: Basal Insulin Analog
Basal insulin analog given SC.
|
Administered SC
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Change From Baseline to Week 24 in Hemoglobin A1c (HbA1c)
Tidsramme: Baseline, 24 Weeks
|
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by analysis of covariance (ANCOVA) model with last observation carried forward (LOCF) and with terms for change from baseline in HbA1c as response, treatment as fixed effect and baseline HbA1c as covariate. |
Baseline, 24 Weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Change From Baseline to Week 48 in HbA1c
Tidsramme: Baseline, 48 Weeks
|
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by ANCOVA model with LOCF and with terms for change from baseline in HbA1c as response, treatment as fixed effect and baseline HbA1c as covariate. |
Baseline, 48 Weeks
|
Percentage of Participants Who Achieve HbA1c <7% at Week 24
Tidsramme: 24 Weeks
|
Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.
|
24 Weeks
|
Percentage of Participants Who Achieve HbA1c <7% at Week 48
Tidsramme: 48 Weeks
|
Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.
|
48 Weeks
|
Change From Baseline to Week 24 in Venous Fasting Plasma Glucose
Tidsramme: Baseline, 24 Weeks
|
Fasting Plasma glucose (FPG) is a test to determine how much glucose (sugar) is in a plasma sample after an overnight fast.
Least Squares (LS) means was determined by ANCOVA model with LOCF and with terms for change from baseline in Venous FPG as response, treatment as fixed effect and baseline Venous FPG as covariate.
|
Baseline, 24 Weeks
|
Change From Baseline to Week 48 in Venous Fasting Plasma Glucose
Tidsramme: Baseline, 48 Weeks
|
Fasting Plasma glucose (FPG) is a test to determine how much glucose (sugar) is in a plasma sample after an overnight fast.
Least Squares (LS) means was determined by ANCOVA model with LOCF and with terms for change from baseline in Venous FPG as response, treatment as fixed effect and baseline Venous FPG as covariate.
|
Baseline, 48 Weeks
|
Change From Baseline to Week 24 in Finger Stick Blood Glucose (FSBG)-Based Fasting Blood Glucose, Post Prandial Glucose
Tidsramme: Baseline, 24 Weeks
|
Fasting blood glucose (FBG) and post prandial glucose (PPG) [pre-breakfast (fasting) and post-breakfast (approximately 2 hours after breakfast)] was measured using FSBG.
LS Mean was measured with ANCOVA model with LOCF and with terms for change from baseline in FSBG-based FBG/PPG as response, treatment as fixed effect and baseline FSBG-based FBG/PPG as covariate.
|
Baseline, 24 Weeks
|
Change From Baseline to Week 48 in Finger Stick Blood Glucose (FSBG)-Based Fasting Blood Glucose, Post Prandial Glucose
Tidsramme: Baseline, 48 Weeks
|
Fasting blood glucose (FBG) and post prandial glucose (PPG) [pre-breakfast (fasting) and post-breakfast (approximately 2 hours after breakfast)] was measured using FSBG.
LS Mean was measured with ANCOVA model with LOCF and with terms for change from baseline in FSBG-based FBG/PPG as response, treatment as fixed effect and baseline FSBG-based FBG/PPG as covariate.
|
Baseline, 48 Weeks
|
Total Daily Insulin Dose at Week 24 and 48
Tidsramme: 24 Weeks, 48 Weeks
|
Total daily insulin dose in the basal insulin analog and in Insulin Analog Mid Mixture group at week 24 and 48.
|
24 Weeks, 48 Weeks
|
Change From Baseline to Week 24 in Body Weight
Tidsramme: Baseline, 24 Weeks
|
LS means were calculated using ANCOVA model with LOCF and with terms for change from baseline in bodyweight as response, treatment as fixed effect and baseline bodyweight as covariate.
|
Baseline, 24 Weeks
|
Change From Baseline to Week 48 in Body Weight
Tidsramme: Baseline, 48 Weeks
|
LS means were calculated using ANCOVA model with LOCF and with terms for change from baseline in bodyweight as response, treatment as fixed effect and baseline bodyweight as covariate.
|
Baseline, 48 Weeks
|
Rate of Hypoglycemia at Week 24 and 48
Tidsramme: 24 Weeks, 48 Weeks
|
Hypoglycemic episodes are defined as events that are associated with reported signs and symptoms of hypoglycemia and/or documented blood glucose (BG) concentrations of ≤70 mg/dL (3.9 mmol/L).
The overall yearly rates (events/participant/year) of those hypoglycemic events, calculated as, for each participant, the number of episodes times 365.25 and then divided by the participants treatment duration, will be summarized, and analyzed by a Negative-binomial regression model with treatment as fixed effects and log of (patient's treatment duration/365.25)
as an offset variable.
|
24 Weeks, 48 Weeks
|
Number of Participants With Insulin Treatment Change at Week 48
Tidsramme: Baseline through 48 Weeks
|
Insulin treatment change can be insulin treatment discontinuation, switch, intensification or reduction in frequency.
|
Baseline through 48 Weeks
|
Percentage of Participants Who Achieve the HbA1c <7% Without Switching and Discontinuing Study Insulin, and Without Using Rescue Therapy at Week 24
Tidsramme: 24 Weeks
|
Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.
Percentages of participants who achieved HbA1c levels of <7% were analyzed using a logistic regression model with logic link function, treatment as fixed effect and baseline HbA1c as continuous covariate.
|
24 Weeks
|
Percentage of Participants Who Achieve the HbA1c <7% Without Switching and Discontinuing Study Insulin, and Without Using Rescue Therapy at Week 48
Tidsramme: 48 Weeks
|
Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A. HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time.
Percentages of participants who achieved HbA1c levels of <7% were analyzed using a logistic regression model with logic link function, treatment as fixed effect and baseline HbA1c as continuous covariate.
|
48 Weeks
|
Change From Baseline to Week 48 in Self-Efficacy About Insulin Therapy Questionnaire (SEITQ) Score
Tidsramme: Baseline, 48 Weeks
|
The SEITQ is designed to measure an individual's self-efficacy related to insulin therapy.
The SEITQ consists of 5 items (that is, statements).
The first 4 statements imply confidence in completing the tasks needed to take insulin correctly and avoid both hyperglycemia and hypoglycemia, whereas the last statement is an outcome expectation and implies that performance of these tasks will lead to avoidance of complications.
Each item score ranges from 1 (strongly disagree) to 7 (strongly agree).
The total SEITQ score is the sum of each item scores, with the range of 5 to 35.
Higher SEITQ score indicates better outcome (higher self-efficacy).
LS Mean was calculated using Mixed Models Analysis (MMRM) for repeated measures with all post-baseline SEITQ as responses, baseline SEITQ as a continuous covariate, treatment group, Visits, and treatment by visit interaction as fixed effects and participant as a random effect.
|
Baseline, 48 Weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 16507
- F3Z-GH-IOQR (Annen identifikator: Eli Lilly and Company)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
IPD-delingstidsramme
Tilgangskriterier for IPD-deling
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
- CSR
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Type 2 diabetes mellitus
-
AstraZenecaRekruttering
-
Daewoong Pharmaceutical Co. LTD.Har ikke rekruttert ennåT2DM (type 2 diabetes mellitus)
-
Zhongda HospitalRekrutteringType 2 diabetes mellitus (T2DM)Kina
-
Newsoara Biopharma Co., Ltd.RekrutteringT2DM (type 2 diabetes mellitus)Kina
-
Shanghai Golden Leaf MedTec Co. LtdAktiv, ikke rekrutterendeType 2 diabetes mellitus (T2DM)Kina
-
SanofiFullført
-
Haisco Pharmaceutical Group Co., Ltd.Fullført
-
PegBio Co., Ltd.FullførtType 2 diabetes mellitus (T2DM)Kina
-
Oramed, Ltd.IntegriumAvsluttetT2DM (type 2 diabetes mellitus)Forente stater
-
Oramed, Ltd.IntegriumFullførtT2DM (type 2 diabetes mellitus)Forente stater
Kliniske studier på Insulin Analog Mid Mixture
-
Nemours Children's ClinicFullførtDiabetes mellitus, insulinavhengigForente stater
-
Mannkind CorporationFullførtType 1 diabetes mellitusForente stater
-
India Diabetes Research Foundation & Dr. A. Ramachandran...Fullført
-
Eli Lilly and CompanyFullførtDiabetes mellitus, type 2Forente stater, Canada, India, Puerto Rico, Australia, Spania, Nederland, Ungarn, Brasil, Hellas, Romania, Argentina
-
Centre Hospitalier Universitaire de BesanconEli Lilly and Company; AstraZenecaFullført
-
Shanghai 6th People's HospitalUkjent
-
Centre Hospitalier Universitaire de BesanconEli Lilly and Company; AstraZenecaFullført
-
Brigham and Women's HospitalPatient-Centered Outcomes Research Institute; McGill University; VA Boston...Aktiv, ikke rekrutterendeType 2 diabetes | Nyresykdom | Kardiovaskulære hendelserForente stater